Does CareFirst BlueCross BlueShield Cover Forteo?

How CareFirst BlueCross BlueShield Classifies Forteo on Its Formulary

CareFirst BCBS places Forteo (teriparatide) on its specialty drug tier across most commercial, small group, and individual marketplace plans. Specialty-tier placement means higher cost-sharing than standard branded medications and mandatory dispensing through a designated specialty pharmacy network.

Formulary Tier and Cost-Sharing Structure

Forteo's classification as a specialty injectable separates it from oral osteoporosis drugs like alendronate, which sit on lower generic tiers. On a typical CareFirst three-tier or four-tier formulary, specialty drugs occupy the highest cost-sharing bracket. Members on plans with coinsurance-based specialty tiers may pay 20% to 33% of the drug's cost after their deductible, which translates to significant monthly expense given Forteo's wholesale acquisition cost of approximately $3,700 per 28-day pen [1]. A fixed-copay specialty tier, where available, usually sets the amount between $100 and $500 per fill.

Medicare Advantage and Federal Employee Plans

CareFirst administers several Medicare Advantage and Federal Employee Health Benefit (FEHB) plans with separate formularies. Medicare Advantage plans covering Forteo must follow CMS Part D guidelines, which require coverage of all injectable osteoporosis drugs meeting USP class standards [2]. The FEHB Blue Cross plan offered through CareFirst lists Forteo under its specialty pharmacy benefit with prior authorization. Federal employees should verify tier placement through the current year's formulary document on the OPM website, as tier assignments can shift during the annual update cycle.

Prior Authorization Requirements for Forteo at CareFirst

Every CareFirst plan requires prior authorization before filling a Forteo prescription. The process exists because teriparatide is expensive and FDA-labeled for patients at high fracture risk, not as first-line therapy for all osteoporosis diagnoses [3].

Clinical Criteria CareFirst Evaluates

CareFirst's pharmacy benefit manager reviews prior authorization requests against a set of clinical criteria. While exact policy language varies by plan year, the standard requirements include:

• A confirmed diagnosis of osteoporosis by dual-energy X-ray absorptiometry (DXA) showing a T-score of -2.5 or lower at the hip, femoral neck, or lumbar spine [4]
• Documentation that the patient tried and failed at least one oral bisphosphonate (typically alendronate 70 mg weekly or risedronate 35 mg weekly) for a minimum of 12 months, OR a documented contraindication or intolerance to bisphosphonates
• History of a fragility fracture, OR a 10-year major osteoporotic fracture probability exceeding 20% on the FRAX calculator [5]
• Prescriber attestation that the requested treatment duration will not exceed 24 months

Some CareFirst plans also accept prior bisphosphonate failure documented by a new fracture occurring during therapy or continued bone mineral density decline of 3% or more despite adherence.

Step Therapy and Why It Matters

Step therapy is the formal name for the "try cheaper drugs first" requirement. The American Association of Clinical Endocrinology (AACE) 2020 guidelines do endorse anabolic agents like teriparatide as initial therapy in very-high-risk patients (those with a recent fracture within 12 months, a T-score below -3.0, or multiple vertebral fractures) [6]. If your physician documents very-high-risk status, CareFirst may waive the bisphosphonate step-therapy requirement. This exception request must be submitted alongside the prior authorization form.

What Forteo Costs With CareFirst Coverage

The actual amount a CareFirst member pays for Forteo depends on deductible status, plan design, and whether the member uses any available copay assistance. Forteo's average wholesale price runs approximately $4,100 for a 28-day supply [7]. After insurer-negotiated discounts, the plan's net cost is lower, but patient cost-sharing is still calculated against the pharmacy's contracted rate.

Deductible Phase

Many CareFirst plans apply the full specialty drug cost toward the annual deductible before coverage kicks in. A member with a $2,000 annual deductible filling Forteo in January would pay the full contracted price for the first fill (or until the deductible is met), then shift to their coinsurance or copay rate for subsequent fills.

Copay and Coinsurance Phase

After the deductible, a CareFirst member on a 30% coinsurance specialty tier would pay roughly $1,000 to $1,200 per month for Forteo based on the contracted rate. Plans with a specialty copay cap (some CareFirst plans cap specialty copays at $150 or $250 per fill) provide more predictable costs. Check the Summary of Benefits and Coverage document for your specific plan.

Out-of-Pocket Maximum Protection

All ACA-compliant CareFirst plans include an annual out-of-pocket maximum. For 2026, the federal ceiling is $9,200 for an individual [8]. Once total in-network cost-sharing hits this cap, CareFirst covers the remaining Forteo fills at 100% for the rest of the plan year. Patients starting Forteo early in the calendar year often reach this maximum within 3 to 5 months if they have other medical expenses.

How to Get Forteo Approved Through CareFirst

The prior authorization process for Forteo involves your prescribing physician, CareFirst's pharmacy benefit team, and often a specialty pharmacy coordinator. Here is the typical sequence.

Step 1: Physician Submits the Request

Your endocrinologist, rheumatologist, or primary care provider completes CareFirst's prior authorization form. This form requires the DXA scan results, fracture history, previous osteoporosis medications tried (with dates and outcomes), and the planned Forteo treatment duration. Most CareFirst PA forms can be submitted electronically through the CoverMyMeds platform or faxed to the number listed on the member's pharmacy benefit card.

Step 2: CareFirst Reviews and Decides

Standard review takes 5 to 10 business days. Urgent requests (defined as situations where delay could seriously jeopardize the patient's health) receive a decision within 72 hours for commercial plans and 24 hours for Medicare Advantage plans per CMS rules [9]. CareFirst notifies both the prescriber and the member of the decision by mail or secure portal message.

Step 3: Specialty Pharmacy Coordination

Once approved, CareFirst routes the prescription to its preferred specialty pharmacy (currently CareFirst's network includes CVS Specialty and Optum Specialty Pharmacy for most plans). The specialty pharmacy contacts the patient to arrange delivery, provide injection training materials, and set up a recurring shipment schedule. Forteo requires refrigeration during shipping, so the pharmacy ships it in temperature-controlled packaging.

What to Do if CareFirst Denies Forteo Coverage

Denials happen. The most common reasons are incomplete documentation, insufficient proof of bisphosphonate failure, or a DXA score that falls above the -2.5 threshold.

Internal Appeal Process

CareFirst members have 180 days from the denial date to file an internal appeal. The appeal should include:

• A letter from the prescribing physician explaining clinical necessity
• Updated DXA results and FRAX scores
• Documentation of prior bisphosphonate therapy (pharmacy claims records, progress notes)
• Relevant guideline citations (AACE 2020 or Endocrine Society 2019 guidelines) supporting teriparatide use in the patient's specific clinical scenario [6][10]

The Vertebral Fracture Trial demonstrated that teriparatide 20 mcg/day reduced new vertebral fractures by 65% and non-vertebral fractures by 53% over a median of 21 months compared to placebo (N=1,637) [11]. The VERO trial (N=1,360) showed teriparatide reduced new vertebral fractures by 56% compared to risedronate over 24 months [12]. Including these trial results in the appeal letter strengthens the medical necessity argument.

External Review

If the internal appeal is denied, Maryland-domiciled CareFirst members can request an independent external review through the Maryland Insurance Administration. Virginia and D.C. Residents have equivalent state-level external review rights. External reviewers are independent physicians who evaluate whether the denial was clinically appropriate. The external review is binding on CareFirst if the reviewer rules in the patient's favor.

Alternatives if Coverage Is Denied or Unaffordable

Not every patient secures Forteo coverage on the first attempt. Several backup options exist.

Eli Lilly Forteo Savings Card

Eli Lilly's manufacturer copay assistance program can reduce out-of-pocket costs to as little as $0 per month for commercially insured patients whose plans cover Forteo but impose high cost-sharing [13]. The card does not apply to government-funded insurance (Medicare, Medicaid, Tricare, VA). Eligible patients can enroll at Lilly's patient support website or through the specialty pharmacy.

Lilly Cares Patient Assistance Program

Uninsured patients or those with a coverage denial may qualify for free Forteo through Lilly Cares. Eligibility is income-based, generally requiring household income at or below 400% of the federal poverty level. The application requires a prescription, proof of income, and documentation of the coverage denial.

Biosimilar and Generic Teriparatide

The FDA approved the first teriparatide biosimilar (Teriparatide, marketed by Alvogen) in 2023, and generic teriparatide options from Pfenex and other manufacturers have entered the market [14]. These alternatives typically sit on lower specialty tiers and may have less restrictive prior authorization criteria than brand-name Forteo. Ask your physician whether CareFirst's formulary includes a teriparatide biosimilar, which could cut costs by 20% to 40%.

Alternative Anabolic Agents

Abaloparatide (Tymlos) is the other FDA-approved anabolic agent for osteoporosis. In the ACTIVE trial (N=2,463), abaloparatide reduced new vertebral fractures by 86% versus placebo over 18 months [15]. CareFirst may cover abaloparatide under different prior authorization criteria. If Forteo is denied, your physician can evaluate whether switching the request to abaloparatide might succeed.

Romosozumab (Evenity), a sclerostin inhibitor, received FDA approval for postmenopausal women at high fracture risk. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced clinical fractures by 27% compared to alendronate alone over a median of 33 months [16]. Romosozumab has a black-box warning for cardiovascular risk and carries its own prior authorization requirements at CareFirst, but it represents another option if teriparatide coverage fails.

Forteo Coverage for Specific Osteoporosis Diagnoses

CareFirst's coverage criteria differ slightly depending on the underlying diagnosis driving the Forteo prescription.

Postmenopausal Osteoporosis

This is the most common indication. CareFirst generally follows the FDA label: postmenopausal women with osteoporosis at high risk for fracture [3]. The step therapy requirement through bisphosphonates applies unless very-high-risk criteria are met.

Glucocorticoid-Induced Osteoporosis

Patients on chronic glucocorticoids (prednisone 5 mg/day or equivalent for 3+ months) face accelerated bone loss. The American College of Rheumatology 2022 guidelines recommend teriparatide as an option for moderate-to-high fracture risk patients on long-term glucocorticoids [17]. CareFirst typically accepts glucocorticoid-induced osteoporosis as a qualifying diagnosis without requiring prior bisphosphonate failure, though documentation of glucocorticoid dose and duration is mandatory.

Male Osteoporosis

Forteo carries FDA approval for men with primary or hypogonadal osteoporosis at high fracture risk [3]. Coverage criteria for men mirror the postmenopausal criteria in most CareFirst plans: DXA-confirmed osteoporosis plus high fracture risk or bisphosphonate failure.

Key Timelines and Practical Tips

Knowing the administrative timeline helps prevent gaps in therapy.

Start the prior authorization process at least 2 weeks before you need the first dose. Specialty pharmacies require 3 to 5 business days for initial enrollment and shipping after PA approval. Forteo pens expire 28 days after first use even if medication remains, so coordinate delivery timing carefully.

Reauthorization is typically required every 6 to 12 months during the 24-month treatment course. Set a calendar reminder 30 days before the current authorization expires so your physician can submit renewal paperwork without a lapse.

If you switch CareFirst plans during open enrollment, the new plan may not honor the previous plan's prior authorization. Confirm Forteo coverage with the new plan before the effective date, and ask your physician to submit a new PA if needed.

Patients on Medicare Advantage through CareFirst should be aware that the Part D coverage gap (donut hole) was fully closed as of 2024, meaning manufacturer discounts and plan payments count toward catastrophic coverage. Once total drug costs exceed the catastrophic threshold ($8,000 in true out-of-pocket costs for 2026), the patient pays $0 or a small copay for the remainder of the year [18].